Pooled in Vivo Experiments
Mosaic Screening is Gordian’s unique version of pooled in vivo (inside the animal) screening in which hundreds of therapies (not just one) are tested in a single sick animal.
Unlike traditional in vivo screening, Mosaic Screening uses animals more representative of human patients with the same disease, creating a complicated biological environment similar to what the therapies will encounter in clinical trials.
Mosaic Screening turns the diseased tissue into a “mosaic,” where different cells receive different therapies independently of each other, each with a unique barcode, while the rest remain unchanged.
We then study the interactions between different cell types, the effects of signals carried by the bloodstream, and how the immune system is affected, among other things.
By analyzing the treated cells and using barcode sequencing, we can identify the specific treatment given to each cell. At the same time, we examine how the treatment affects the disease biology in an environment very similar to where a clinical drug would need to be effective.
Gene therapy is fulfilling the promise of miracle cures for rare diseases. But even as delivery technology countries to mature, the field has yet to make headway for much more common complex diseases because of target risk. At Gordian, we leverage proven gene therapy delivery technology to screen thousands of targets for these diseases, eliminating this barrier.
-
Patient Avatars
Patient Avatars are animals that are most closely representative of human patients with age-related diseases, and have often acquired the disease naturally.
Read More about Patient Avatars.
-
Pythia
Instead of focusing on just one hypothesis about a specific disease, Gordian’s Pythia examines the entire transcriptome (the complete set of RNA molecules expressed from the Patient Avatar’s genes) to see how potential therapies affect various cellular pathways.
Read More about Pythia.